Antibiotics: Where did we go wrong?

Drug Discovery Today

Volumn 10, Issue 1, 2005, Pages 45-52

  Overbye, Karen M ^a   Barrett, John F ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Biotechnology; Clincical development; Development; Drug Discovery; MRSA; Natural products; Pharmaceutical Science; Resistance; Tuberculosis

Indexed keywords

1 (6 AMINO 3,5 DIFLUORO 2 PYRIDYL) 8 CHLORO 6 FLUORO 1,4 DIHYDRO 7 (3 HYDROXY 1 AZETIDINYL) 4 OXO 3 QUINOLINECARBOXYLIC ACID; 7 [[(2 AMINO 5 CHLORO 4 THIAZOLYL)(HYDROXYIMINO)ACETYL]AMINO] 3 [[3 [[(2 AMINOETHYL)THIO]METHYL] 4 PYRIDINYL]THIO] 8 OXO 5 THIA 1 AZABICYCLO[4.2.0]OCT 2 ENE 2 CARBOXYLIC ACID; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; B 883698; B 8883698; BLEOMYCIN; BMS 264756; CARBAPENEM DERIVATIVE; CEFTOBIPROLE MEDOCARIL; CEPHALOSPORIN; CS 023; DALBAVANCIN; DAPTOMYCIN; DOXORUBICIN; GLYCOPEPTIDE; HYDROXAMIC ACID; LINEZOLID; MACROLIDE; MC 04124; MC 04546; MP 04124; MP 601205; N (5 FLUORO 1 OXIDO 2 PYRIDINYL) 1 [2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANOYL]PROLINAMIDE; ORITAVANCIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; PEPTIDE DERIVATIVE; PNU 288034; QUINOLONE DERIVATIVE; RAMOPLANIN; RIFALAZIL; RIFAMYCIN DERIVATIVE; RW 3333441; RWJ 442381; RWJ 442831; TELAVANCIN; TELITHROMYCIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; VRC 4887; WCK 771A;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; BIOTECHNOLOGY; CAUSE OF DEATH; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HUMAN; KLEBSIELLA PNEUMONIAE; MEDICAL RESEARCH; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; PSEUDOMONAS AERUGINOSA; PUBLIC HEALTH; REVIEW; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; DRUG INDUSTRY; DRUG RESISTANCE, BACTERIAL; GENOMICS; TECHNOLOGY, PHARMACEUTICAL;

EID: 12844274375     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)03285-4     Document Type: Review

References (69)

1. Walsh C. Where will the new antibiotics come from? Nat. Rev. Microbiol. 1:2003;65-70
2. Finch R. Bacterial resistance - the clinical challenge. Clin. Microbiol. Infect. 8:(Suppl. 3):2002;21-32
3. Chopra I., et al. Exploiting current understanding of antibiotic action for the discovery of new drugs. J. Appl. Microbiol. 92:2002;4S-15S
4. Douthwaite S. Structure-activity relationships of ketolides versus macrolides. Clin. Microbiol. Infect. 7:(Suppl. 3):2001;11-17
5. Bonfiglio G., et al. Recent developments in carbapenems. Expert Opin. Investig. Drugs. 11:2002;529-544
6. Smith J.T., Lewin C.S. Mechanisms of antimicrobial resistance and implications for epidemiology. Vet. Microbiol. 35:1993;233-242
7. Lakaye B., et al. When drug inactivation renders the target irrelevant to antibiotic resistance: a case story with beta-lactams. Mol. Microbiol. 31:1999;89-101
8. Haddad J., et al. Design of novel antibiotics that bind to the ribosomal acyltransfer site. J. Am. Chem. Soc. 124:2002;3229-3237
9. Therrien C., Levesque R.C. Molecular basis of antibiotic resistance and beta-lactamase inhibition by mechanism-based inactivators: perspectives and future directions. FEMS Microbiol. Rev. 24:2000;251-262
10. Xiong Y.Q., et al. Linezolid: a new antibiotic. Drugs Today. 36:2000;631-639
11. Rachakonda S., Cartee L. Challenges in antimicrobial drug discovery and the potential of nucleoside antibiotics. Curr. Med. Chem. 11:2004;775-793
12. Avorn, J.L. (1987-2000) Antibiotic Resistance: Synthesis of Recommendations by Expert Policy Groups 2000. Commissioned by the World Health Organization (http://www.who.int/emc/amrpdfs/ Antimicrobial_resistance_recommendations_of_expert_polic.pdf)
13. Garrett L. The Coming Plague: Newly Emerging Diseases in a World Out of. 2004;Balance Penguin.
14. B-Shnayerson M., Plotkin M.J. The Killers Within: Deadly Rise of Drug Resistant Bacteria. 2002;Little Brown and Company
15. Barker K.F. Antibiotic resistance: a current perspective. Br. J. Clin. Pharmacol. 48:1995;109-124
16. Cohen M.L. Changing patterns of infectious diseases. Nature. 406:2000;762-767
17. Guerrant R.L., Blackwood B.L. Threats to a global survival: the growing crisis of infectious diseases - our unfinished agenda. Clin. Infect. Dis. 28:1999;966-986
18. Barrett C.T., Barrett J.F. Antibacterials: are the new entries enough to deal with the emerging resistance problems? Curr. Opin. Biotechnol. 14:2003;621-626
19. Progan S.J. Why is Pharma getting out of antibacterial drug discovery. Curr. Opin. Microbiol. 6:2003;427-430
20. Projan S. New (and not so new) antibacterial targets - from where and when will the novel drugs come? Curr. Opin. Pharmacol. 2:2002;513-522
21. Silver L.L. Novel inhibitors of bacterial cell wall synthesis. Curr. Opin. Microbiol. 6:2003;431-438
22. Abbanat D., et al. Novel antibacterial agents for the treatment of serious Gram-positive infections. Expert Opin. Investig. Drugs. 12:2003;379-399
23. Phillips O.A. Antibacterial agents: patent highlights July to December 2002. Curr. Opin. Investig. Drugs. 4:2003;117-127
24. Bronson J., Barrett J.F. Quinolones, everninomycins, glycylglycines, carbapenems, lipopeptides, and cephem antibacterials in clinical development. Curr. Med. Chem. 8:2001;1775-1793
25. Johnson A.P. The future prospects of oxazolidinones. IDrugs. 6:2003;240-245
26. Demain A.J. Prescription for an ailing pharmaceutical industry. Nat. Biotechnol. 20:2002;331
27. Shlaes D.M., et al. Antibiotic discovery: state of the State. ASM News. 70:2002;275-281
28. Bush K. Why it is important to continue antibacterial drug discovery? ASM News. 70:2004;282-287
29. Shain C.S. Telithromycin: the first of the ketolides. Ann. Pharmacother. 36:2002;452-464
30. Anonymous Daptomycin (cubicin) for skin and soft tissue infections. Med. Lett. Drugs Ther. 46:2004;11-12
31. AnonymousGemifloxacin. Factive, LB 20304, SB 265805. Drugs in R&D. 3:2003;258-270
32. Silver L., Bostian K. Screening of natural products for antimicrobial agents. Eur. J. Clin. Microbiol. Infect. Dis. 9:1990;455-461
33. Topliss J.G., et al. Natural and synthetic substances related to human health. Pure Appl. Chem. 74:2002;1957-1985
34. Centers for Disease Control and PreventionNational nosocomial infections surveillance (NNIS) system report, data summary from January 1992 to June 2003, Am. J. Infect. Control 31, 481-498
35. Mathai D., et al. Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia: I - results from the SENTRY antimicrobial surveillance program. Diagn. Microbiol. Infect. Dis. 39:2001;105-116
36. Ichiyama S., et al. Nationwide sensitivity surveillance of various antibiotic activities against bacteria isolated from patients with severe infections. Jpn. J. Antibiot. 54:2001;401-447
37. Ehrhardt A.F., Russo R. Clinical resistance encountered in the respiratory surveillance program (RESP) study: a review of the implications for the treatment of community-acquired respiratory tract infections. Am. J. Med. 111:(Suppl. 9A):2001;30S-38S
38. Andrade S.S., et al. Increasing prevalence of antimicrobial resistance among Pseudomonas aeruginosa isolates in Latin American medical centres: 5 year report of the SENTRY antimicrobial surveillance program (1997-2001). J. Antimicrob. Chemother. 52:2003;140M-141M
39. Tunidge J., et al. Low levels of fluoroquinolone resistance in Escherichia coli. A five year trend in Australia measured through the use of TSN database Australia. Commun. Dis. Intell. 27:(Suppl.):2003;S89-S91
40. Urban C., et al. Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. Clin. Infect. Dis. 36:2003;1268-1274
41. Felmingham D. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance program. Prospective resistant organism tracking and epidemiology for the ketolide telithromycin. J. Infect. 44:(Suppl. A):2002;3-10
42. Sefton A.M. Mechanisms of antimicrobial resistance: their clinical relevance in the new millennium. Drugs. 62:2002;557-566
43. Dougherty T.J., et al. Antimicrobial resistance - why do we have it and what can we do about it? Expert Opin. Investig. Drugs. 9:2000;1707-1709
44. Monroe S., Polk R. Antimicrobial use and bacterial resistance. Curr. Opin. Microbiol. 3:2000;496-501
45. Barlow M., Hall B.G. Experimental prediction of the natural evolution of antibiotic resistance. Genetics. 163:2003;1237-1241
46. Barrett J.F. Antimicrobial resistance - should we be concerned. Expert Opin. Pharmacother. 2:2001;201-204
47. Chopra I., et al. The role of mutators in the emergence of antibiotic-resistant bacteria. Drug Resist. Updat. 6:2003;137-145
48. Ruiz J. Mechanisms of resistance to quinolones: targterations, decreased accumulation and DNA gyrase protection. J. Antimicrob. Chemother. 51:2003;1109-1117
49. Jones R.N., Pfaller M.A. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program. Clin. Infect. Dis. 31:(Suppl. 2):2000;S16-S23
50. Raveh D., et al. Susceptibility trends in bacteraemias: analyses of 7544 patient-unique bacteraemic episodes spanning 11 years (1990-2000). J. Hosp. Infect. 55:2003;196-203
51. Corbett E.L., et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern. Med. 163:2003;1009-1021
52. Thornberry N.A., et al. Mechanism-based inactivation of alanine racemase by 3-halovinylglycines. J. Biol. Chem. 266:1991;21657-21665
53. Wu F.T., et al. Recent studies of bioactive substances produced by endophyte. Chinese J. Antibiot. 29:2004;184-192
54. Concha N., Long P.F. Mining the microbial metabolome: A new frontier for natural product lead discovery. Drug Discov. Today. 8:2003;1078-1084
55. Khandurina J., Guttman A. Microchip-based high-throughput screening analysis of combinatorial libraries. Curr. Opin. Chem. Biol. 6:2002;359-366
56. Kaeberlein T., et al. Isolating 'uncurtivable' microorganisms in pure culture in a simulated natural environment. Science. 296:2002;1127-1129
57. Fleischmann R.D., et al. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science. 269:1995;496-512
58. Forsyth A.R., et al. A genome-wide strategy for the identification of essential genes in Staphylococcus aureus. Mol. Microbiol. 43:2002;1387-1400
59. McDevitt D., et al. Novel targets for the future development of antibacterial agents. J. Appl. Microbiol. 92:2002;28S-34S
60. Waterman S.R. Bacterial genomics as a potential tool for discovering new antimicrobial agents. Am. J. Pharmacogenomics. 1:2002;263-269
61. Loferer H. Mining bacterial genomes for antimicrobial targets. Mol. Med. Today. 6:2000;470-474
62. DeRisi J.L., et al. Exploring the metabolic and genetic control of gene expression on a genomic scale. Science. 278:1997;680-686
63. Chee M., et al. Accessing genetic information with high-density DNA arrays. Science. 274:1996;610-614
64. Harrington C.A., et al. Monitoring gene expression using DNA microarrays. Curr. Opin. Microbiol. 3:2000;285-291
65. Pandey A., Mann M. Proteomics to study genes and genomes. Nature. 405:2000;837-846
66. Washburn M.P., Yates J.R. Analysis of the microbial proteome. Curr. Opin. Microbiol. 3:2000;292-297
67. Gootz T.D., Brighty K.E. Chemistry and mechanism of the quinolone antibacterials. In The Quinolones. 2nd ed. :1998;Academic Press
68. Tyler V.E., et al. Pharmacognosy. 1988;Lea and Febiger
69. Ray A., Rice L.B. Wildcatters welcome: the need for new antimicrobial agents. Therapy. 1:1998;1-5